2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2016
Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia
Lerner MZ, Lerner BA, Patel AA, Blitzer A. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia. The Laryngoscope 2016, 127: 1131-1134. PMID: 27633917, DOI: 10.1002/lary.26265.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOnabotulinum toxinChart reviewFemale groupOnabotulinum Toxin A InjectionsRetrospective chart reviewBotulinum toxin injectionSenior author's databaseAbductor spasmodic dysphoniaIndependent sample twoA injectionAverage followSymptom controlOromandibular dystoniaToxin injectionFemale patientsRetrospective reviewAlternate diagnosisBotulinum toxinAntibody formationFemale genderPossible inverse relationshipInclusion criteriaThyroarytenoid muscle